NBIX vs TECH · P/E 45, rev $2.36B vs P/E 65, rev $1.22B
Neurocrine Biosciences Inc (NBIX) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the NBIX and TECH stock pages for the full models.
Not investment advice.